為什么呼吸道病毒會引起胃腸道癥狀?這是自2019年年底新冠疫情爆發(fā)以來,我們都在思考的問題。
自新冠疫情爆發(fā)以來,新冠病毒感染者報告了一系列癥狀,超出了你可能預(yù)期的呼吸道癥狀,包括腹瀉、惡心、胃痛和食欲不振等胃腸道疾病。
研究人員可能已經(jīng)發(fā)現(xiàn)了其中的原因。羅格斯大學(xué)(Rutgers University)于11月28日發(fā)布的一項新研究顯示,與沒有感染新冠病毒的健康人相比,新冠病毒感染者微生物群中的細菌水平較低。
研究人員收集了60人的糞便樣本:20名感染新冠病毒后正處于發(fā)作期的患者,20名從未感染過新冠病毒的人,20名感染新冠病毒后已經(jīng)康復(fù)的人。他們發(fā)現(xiàn),與那些沒有感染或者感染后已經(jīng)康復(fù)的人相比,感染新冠病毒后正處于發(fā)作期的患者體內(nèi)55種細菌的數(shù)量存在差異。
研究人員發(fā)現(xiàn),通常而言,一些“對人體有益的細菌”,如擬桿菌科和瘤胃球菌科被耗盡,而其他的如普氏棲糞桿菌和短優(yōu)桿菌群則低于最佳水平。感染后,普雷沃氏菌科的數(shù)量則持續(xù)過多。
這項研究始于2020年5月,于2021年1月結(jié)束,研究對象是新冠疫情早期的患者。這項研究的作者之一馬丁·布拉澤博士在一份聲明中稱,在那段時間里,在疫苗和Paxlovid等抗病毒療法出現(xiàn)之前,醫(yī)生通常會讓新冠病毒感染者服用一個療程的抗生素,試圖清除其體內(nèi)可能存在的任何繼發(fā)感染。
布拉澤表示,無論服用抗生素與否,新冠病毒感染者或者之前感染過的人的腸道微生物群都存在差異。但在接受過抗生素治療的患者中,這些問題更為明顯。
羅格斯大學(xué)人類微生物組亨利·羅格斯主席(Henry Rutgers Chair of the Human Microbiome)、該校高級生物技術(shù)和醫(yī)學(xué)中心(Center for Advanced Biotechnology and Medicine)主任布拉澤說:“我們發(fā)現(xiàn),盡管新冠病毒感染者和沒有感染新冠病毒的人之間存在差異,但與其他人差異最大的是那些服用了抗生素的人?!?/p>
作者表示,這項研究的發(fā)現(xiàn)可能最終會導(dǎo)致專門為新冠病毒感染者開發(fā)益生菌。
今年,在向Zoe Health Study報告新冠癥狀的數(shù)百萬人中,胃腸道癥狀仍然非常普遍,這令人難以置信。該研究由哈佛大學(xué)(Harvard University)和斯坦福大學(xué)(Stanford University)的科學(xué)家進行,基于數(shù)百萬美國和英國參與者提交的數(shù)據(jù)。這些參與者通過應(yīng)用程序記錄了自己的癥狀,這些數(shù)據(jù)用于研究目的。
但報告給這項研究的新冠陽性檢測結(jié)果的數(shù)量比去年有所下降。這表明,雖然奧密克戎毒株感染者仍然有胃腸道癥狀,但其胃腸道癥狀沒有德爾塔毒株感染者那么嚴重。此外,研究人員最近寫道,像諾如病毒引發(fā)的腸胃感染可能也是原因之一。(財富中文網(wǎng))
譯者:中慧言-王芳
為什么呼吸道病毒會引起胃腸道癥狀?這是自2019年年底新冠疫情爆發(fā)以來,我們都在思考的問題。
自新冠疫情爆發(fā)以來,新冠病毒感染者報告了一系列癥狀,超出了你可能預(yù)期的呼吸道癥狀,包括腹瀉、惡心、胃痛和食欲不振等胃腸道疾病。
研究人員可能已經(jīng)發(fā)現(xiàn)了其中的原因。羅格斯大學(xué)(Rutgers University)于11月28日發(fā)布的一項新研究顯示,與沒有感染新冠病毒的健康人相比,新冠病毒感染者微生物群中的細菌水平較低。
研究人員收集了60人的糞便樣本:20名感染新冠病毒后正處于發(fā)作期的患者,20名從未感染過新冠病毒的人,20名感染新冠病毒后已經(jīng)康復(fù)的人。他們發(fā)現(xiàn),與那些沒有感染或者感染后已經(jīng)康復(fù)的人相比,感染新冠病毒后正處于發(fā)作期的患者體內(nèi)55種細菌的數(shù)量存在差異。
研究人員發(fā)現(xiàn),通常而言,一些“對人體有益的細菌”,如擬桿菌科和瘤胃球菌科被耗盡,而其他的如普氏棲糞桿菌和短優(yōu)桿菌群則低于最佳水平。感染后,普雷沃氏菌科的數(shù)量則持續(xù)過多。
這項研究始于2020年5月,于2021年1月結(jié)束,研究對象是新冠疫情早期的患者。這項研究的作者之一馬丁·布拉澤博士在一份聲明中稱,在那段時間里,在疫苗和Paxlovid等抗病毒療法出現(xiàn)之前,醫(yī)生通常會讓新冠病毒感染者服用一個療程的抗生素,試圖清除其體內(nèi)可能存在的任何繼發(fā)感染。
布拉澤表示,無論服用抗生素與否,新冠病毒感染者或者之前感染過的人的腸道微生物群都存在差異。但在接受過抗生素治療的患者中,這些問題更為明顯。
羅格斯大學(xué)人類微生物組亨利·羅格斯主席(Henry Rutgers Chair of the Human Microbiome)、該校高級生物技術(shù)和醫(yī)學(xué)中心(Center for Advanced Biotechnology and Medicine)主任布拉澤說:“我們發(fā)現(xiàn),盡管新冠病毒感染者和沒有感染新冠病毒的人之間存在差異,但與其他人差異最大的是那些服用了抗生素的人。”
作者表示,這項研究的發(fā)現(xiàn)可能最終會導(dǎo)致專門為新冠病毒感染者開發(fā)益生菌。
今年,在向Zoe Health Study報告新冠癥狀的數(shù)百萬人中,胃腸道癥狀仍然非常普遍,這令人難以置信。該研究由哈佛大學(xué)(Harvard University)和斯坦福大學(xué)(Stanford University)的科學(xué)家進行,基于數(shù)百萬美國和英國參與者提交的數(shù)據(jù)。這些參與者通過應(yīng)用程序記錄了自己的癥狀,這些數(shù)據(jù)用于研究目的。
但報告給這項研究的新冠陽性檢測結(jié)果的數(shù)量比去年有所下降。這表明,雖然奧密克戎毒株感染者仍然有胃腸道癥狀,但其胃腸道癥狀沒有德爾塔毒株感染者那么嚴重。此外,研究人員最近寫道,像諾如病毒引發(fā)的腸胃感染可能也是原因之一。(財富中文網(wǎng))
譯者:中慧言-王芳
Why would a respiratory virus cause GI symptoms? It’s a question we’ve all been wondering since COVID hit the scene in late 2019.
Since the beginning of the pandemic, patients who came down with the virus have reported a wide range of symptoms beyond the respiratory issues you might expect, including GI ailments like diarrhea, nausea, stomach pains, and loss of appetite.
Researchers may have just discovered why. Levels of bacteria in COVID patients’ microbiomes were off when compared to those of healthy patients who hadn’t experienced COVID, according to a new study from Rutgers University, released on November 28.
Researchers collected stool samples from 60 individuals: 20 who had active COVID infections, 20 who had never experienced COVID, and 20 who had recovered from it. They found differences in the quantities of 55 bacterial species in those with active COVID, when compared to those who hadn’t experienced infection or had recovered from it.
Levels of some generally “good bacteria” like Bacteroidaceae and Ruminococcaceae were depleted, while others like Faecalibacterium and the Eubacterium brachy group were below optimal levels, researchers found. And an overabundance of Prevotellaceae continued after infection.
The study, which began in May 2020 and wrapped up in January 2021, looked at patients early in the pandemic. During that time, before vaccines and antiviral treatments like Paxlovid, it was common for doctors to treat COVID patients with a round of antibiotics, in an attempt to rid the body of any secondary infections that may exist, Dr. Martin Blaser, an author of the study, said in a statement.
Differences in the gut microbiomes of people with COVID, or those who had previously been infected, existed regardless of antibiotic use, according to Blaser. But they were more pronounced in patients who had been treated with antibiotics.
“What we found was that, while there were differences between people who had COVID-19 and those who were not ill, the biggest difference from others was seen in those who had been administered antibiotics,” said Blaser, the Henry Rutgers Chair of the Human Microbiome at Rutgers University, as well as a director of the university’s Center for Advanced Biotechnology and Medicine.
The study’s findings may eventually lead to the development of probiotics specifically for people who come down with COVID, the authors state.
GI symptoms are still incredibly prevalent this year among the millions who report COVID symptoms to the Zoe Health Study. Run by scientists at Harvard and Stanford universities, it’s based on data submitted by millions of U.S. and U.K. participants who log their symptoms via an app for research purposes.
But the number of positive COVID tests reported to the study is down this year over last year. This suggests that while Omicron still features GI symptoms, it doesn’t do so at a greater level than Delta did. What’s more, a stomach bug like norovirus may contribute, researchers recently wrote.